Trimodality Vs Chemoradiation and Salvage Resection in CN2 Stage IIIA Non-Small Cell Lung Cancer

Overview

Journal Semin Thorac Cardiovasc Surg

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2019 Jun 21

PMID 31220530

Citations 5

Authors

Jason C Ye

Li Ding

Scott M Atay

Jorge J Nieva

P Michael McFadden

Eric Chang

Anthony W Kim

Affiliations

Soon will be listed here.

Abstract

To determine the overall survival (OS) in patients who underwent planned trimodality therapy (TMT) and those who underwent definitive concurrent chemoradiation (CRT), but later received salvage resection (SR) for stage IIIA (cN2) (AJCC 7th ed.) non-small cell lung cancer. National Cancer Database data set from 2004 to 2014 was queried. TMT was defined as multiagent CRT with dose >45 Gy, followed by lobectomy or pneumonectomy ≤90 days from end of CRT. SR was defined as multiagent CRT with dose >59 Gy and lobectomy or pneumonectomy performed >90 days from CRT completion. Propensity score weighting and propensity score matching methods were used to balance patient and tumor characteristics and to calculate hazard ratios. A total of 2025 (1899 TMT and 126 SR) patients were analyzed. TMT and SR groups shared similar characteristics. Surgery occurred at a median of 41 days (range 1-90) after CRT in the TMT group and 114 days (91-440) in the SR group. The 90-day mortality after surgery was 6.5% for TMT and 5% for SR (P = 0.43). The 3- and 5-year OS were 55.1% and 35.7% for TMT and 51.6% and 45.0% for SR (P = 0.92, 0.68), with no difference across unadjusted cohort and propensity-adjusted cohort. Patients with cN2 stage IIIA non-small cell lung cancer treated in the United States with definitive CRT followed by SR had similar OS as upfront TMT with similar postoperative mortality despite SR occurring >90 days after >59 Gy CRT. SR remains an option for medically appropriate patients after definitive dose CRT.

Citing Articles

Salvage lung resection after immunotherapy is feasible and safe.

Nemeth A, Canavan M, Zhan P, Udelsman B, Ely S, Wigle D JTCVS Open. 2024; 20:141-150.

PMID: 39296459 PMC: 11405986. DOI: 10.1016/j.xjon.2024.03.018.

Salvage surgery and conversion surgery for patients with nonsmall cell lung cancer: a narrative review.

Yan H, Zheng X, Zeng Y, Wan J, Chen J, Deng Z Int J Surg. 2024; 111(1):1032-1041.

PMID: 38990285 PMC: 11745611. DOI: 10.1097/JS9.0000000000001921.

Underutilization of Systemic Therapy in Patients With NSCLC Undergoing Pneumonectomy: A Missed Opportunity for Survival.

Rodriguez-Quintero J, Kamel M, Dawodu G, Elbahrawy M, Vimolratana M, Chudgar N JTO Clin Res Rep. 2023; 4(8):100547.

PMID: 37644968 PMC: 10460993. DOI: 10.1016/j.jtocrr.2023.100547.

Select octogenarians with stage IIIa non-small cell lung cancer can benefit from trimodality therapy.

Tang A, Feczko A, Murthy S, Raja S, Bribriesco A, Schraufnagel D JTCVS Open. 2022; 10:395-403.

PMID: 36004217 PMC: 9390188. DOI: 10.1016/j.xjon.2022.01.022.

Results of emergency salvage lung resection after chemo- and/or radiotherapy among patients with lung cancer.

Hino H, Utsumi T, Maru N, Matsui H, Taniguchi Y, Saito T Interact Cardiovasc Thorac Surg. 2022; 35(1).

PMID: 35253874 PMC: 9714598. DOI: 10.1093/icvts/ivac043.

References

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Bauman J, Mulligan M, Martins R, Kurland B, Eaton K, Wood D . Salvage lung resection after definitive radiation (>59 Gy) for non-small cell lung cancer: surgical and oncologic outcomes. Ann Thorac Surg. 2008; 86(5):1632-8. DOI: 10.1016/j.athoracsur.2008.07.042. View

Kong F, Ten Haken R, Eisbruch A, Lawrence T . Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol. 2005; 32(2 Suppl 3):S42-54. DOI: 10.1053/j.seminoncol.2005.03.009. View

Little A, Greer Gay E, Gaspar L, Stewart A . National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer. 2007; 57(3):253-60. DOI: 10.1016/j.lungcan.2007.03.012. View

Eberhardt W, Pottgen C, Gauler T, Friedel G, Veit S, Heinrich V . Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015; 33(35):4194-201. DOI: 10.1200/JCO.2015.62.6812. View

Yalman D . Neoadjuvant radiotherapy/chemoradiotherapy in locally advanced non-small cell lung cancer. Balkan Med J. 2015; 32(1):1-7. PMC: 4342120. DOI: 10.5152/balkanmedj.2014.14573. View

Sonett J, Suntharalingam M, Edelman M, Patel A, Gamliel Z, Doyle A . Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg. 2004; 78(4):1200-5. DOI: 10.1016/j.athoracsur.2004.04.085. View

McCaffrey D, Griffin B, Almirall D, Slaughter M, Ramchand R, Burgette L . A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013; 32(19):3388-414. PMC: 3710547. DOI: 10.1002/sim.5753. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379(24):2342-2350. DOI: 10.1056/NEJMoa1809697. View

10.

Kuzmik G, Detterbeck F, Decker R, Boffa D, Wang Z, Oliva I . Pulmonary resections following prior definitive chemoradiation therapy are associated with acceptable survival. Eur J Cardiothorac Surg. 2013; 44(1):e66-70. DOI: 10.1093/ejcts/ezt184. View

11.

Vinod S, Wai E, Alexander C, Tyldesley S, Murray N . Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada. J Thorac Oncol. 2012; 7(7):1155-63. DOI: 10.1097/JTO.0b013e31824fea07. View

12.

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Chirieac L . Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(4):504-535. DOI: 10.6004/jnccn.2017.0050. View

13.

Dickhoff C, Dahele M, Paul M, van de Ven P, de Langen A, Senan S . Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer. Lung Cancer. 2016; 94:108-13. DOI: 10.1016/j.lungcan.2016.02.005. View

14.

Fournel P, Robinet G, Thomas P, Souquet P, Lena H, Vergnenegre A . Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01.... J Clin Oncol. 2005; 23(25):5910-7. DOI: 10.1200/JCO.2005.03.070. View

15.

Casiraghi M, Maisonneuve P, Piperno G, Bellini R, Brambilla D, Petrella F . Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer. Semin Thorac Cardiovasc Surg. 2017; 29(2):233-241. DOI: 10.1053/j.semtcvs.2017.02.001. View

16.

Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S . Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999; 17(9):2692-9. DOI: 10.1200/JCO.1999.17.9.2692. View

17.

Austin P . The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2013; 33(7):1242-58. PMC: 4285179. DOI: 10.1002/sim.5984. View

18.

Albain K, Swann R, Rusch V, Turrisi 3rd A, Shepherd F, Smith C . Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009; 374(9687):379-86. PMC: 4407808. DOI: 10.1016/S0140-6736(09)60737-6. View

19.

Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H . Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol. 1998; 16(2):622-34. DOI: 10.1200/JCO.1998.16.2.622. View

20.

Novakova-Jiresova A, van Luijk P, Goor H, Kampinga H, Coppes R . Changes in expression of injury after irradiation of increasing volumes in rat lung. Int J Radiat Oncol Biol Phys. 2007; 67(5):1510-8. DOI: 10.1016/j.ijrobp.2006.11.058. View